PHONE 1.800.411.4363 FAX 1.800.434.9850 CONNECT

PRENATAL COMPREHENSIVE REQUISITION

PATIENT INFORMATION (COMPLETE ON	E FORM FOR EA	CH PERSON TESTED)				
Fetus of: Patient Last Name		Patient Fir	st Name			/ / e of Birth (MM / DD / YYYY)
Address		City Multiple gestation?	Donor used?	State Zip Patient discharged	Genetic Sex:	Phone
Accession # Hospital / Med	lical Record #	Yes No If yes, sample from fetus	Please specify:	from the hospital/facility: Yes No	Female Gender ident from above):	Male Unknown
REPORTING RECIPIENTS						
Ordering Physician			Institution Name			
Email (Required for International Clients)			Phone		Fax	
ADDITIONAL RECIPIENTS						
Name			Email		Fax	
Name			Email			
PAYMENT (FILL OUT ONE OF THE OPTIC	ONS BELOW)					
SELF PAYMENT						
Pay With Sample 🗌 Bill T	o Patient					
O INSTITUTIONAL BILLING						
Institution Name	Institu	tion Code Inst	itution Contact Name	Institution Phon	ie Ins	stitution Contact Email
Do Not Perform Test Until Patient	t is Aware of Out-	Of-Pocket Costs (exclud	es prenatal testing)			
REQUIRED ITEMS 1. Copy of the F	Front/Back of Insura	nce Card(s) 2. ICD10 D	liagnosis Code(s) 3. Nar	ne of Ordering Physician	4. Insured Signature	of Authorization
	/	/	:		/	/
Name of Insured	Insured Date o	f Birth (MM / DD / YYYY)	Name of Insu	red	Insured Dat	e of Birth (MM / DD / YYYY)
Patient's Relationship to Insured	Phone of Insur	ed	Patient's Rela	tionship to Insured	Phone of In	sured
Address of Insured			Address of In	sured		
City	State	Zip	City		State	Zip
Primary Insurance Co. Name	Primary Insura	ance Co. Phone	Secondary In	surance Co. Name	Secondary	Insurance Co. Phone
Primary Member Policy #	Primary Memb	per Group #	Secondary M	ember Policy #	Secondary	Member Group #
By signing below, I hereby authorize Bay	lor Genetics to p		· · · · ·		results, for proce	
understand that I am responsible for any c reasons including, but not limited to, non- directly from my insurance company in pa	covered and non-	ce, and unmet deductib authorized services. I u	le that the insurance pol Inderstand that I am resp	icy dictates, as well as an consible for sending Bayl		ssing my insurance claim. by my insurance carrier for
reasons including, but not limited to, non-	covered and non-	ce, and unmet deductib authorized services. I u	le that the insurance pol nderstand that I am resp dicare does not cover rou	icy dictates, as well as an consible for sending Bayl	or Genetics any an	ssing my insurance claim. by my insurance carrier fo

This test is medically necessary for the risk assessment, diagnosis, or detection of a disease, illness, impairment, symptom, syndrome, or disorder. The results will determine my patient's medical management and treatment decisions. The person listed as the Ordering Physician is authorized by law to order the test(s) requested herein. I confirm that I have provided genetic testing information to the patient and they have consented to genetic testing.

/	/	
Date	(MM / DD / YYYY)	

Physician's Printed Name

Physician's Signature

PHONE 1.800.411.4363 FAX 1.800.434.9850 CONNECT

PRENATAL COMPREHENSIVE REQUISITION

			/ /	
Fetus of: Patient Last Name	Patient First Name	MI	Date of Birth (MM / DD /)	YYYY) Genetic Sex
ETHNICITY				
 African American Ashkenazi Jewish East Asian (China, Japan, Korea) Finnish French Canadian 	 Hispanic American Mennonite Middle Eastern (Saudi Arabia, Qatar, Iraq, Tu Native American Northern European Caucasian (Scandinaviar 		South Asian (India, Paki	nes, Micronesia, Malaysia, Indonesia) istan) am, Cambodia, Thailand) icasian (Spain, Italy, Greece)
SAMPLE				
Date of Collection (MM / DD / YYYY) (REQUIF	RED) /			
SAMPLE TYPE		GESTATIONAL II	NFORMATION' ·····	
	cc mg □ TA □ TC cc Yes ○ No		n U/S Date: weeks	/ days / a Fetoprotein (AFAFP)
Note: Parental samples are required for Ch	romosomal Microarray Analysis (CMA) and positiv			ariant testing.
Paternal / /	tion (MM/DD/YYYY) / tion (MM/DD/YYYY) Paternal Last Name	Pater	nal First Name	///
Other Family Member	/	st Name Other	r Family Member First Name	// Date of Birth (MM/DD/YYYY)
Note: Parental and familial samples should	be collected in an EDTA tube (5-7cc) for blood or	buccal swab and lab	eled with name and date of birtl	h.
INDICATION FOR TESTING (REQUIRED)				
ICD-10 Diagnosis Code(s):		Abnormal U/S	5 (Specify)	
 Pregnancy at Risk for Specific Genetic Variant/Disorder Specific Prenatal Test 		Multiple Preg	nancy Losses	
Advanced Maternal Age (AMA)		O Parental Cond	cern	
Abnormal Maternal Screen	Other:	🔵 Other Indicati	on (Attach Report and Specify)	
Abnormal cell-free DNA (attach report))			

CONNECT



PRENATAL COMPREHENSIVE REQUISITION

Fetus of: Patient Last Nan	ne	Patient Firs	st Name		I	MI I	Date of Bir	th (MM / DD / YYYY)	Genetic Sex
KNOWN FAMILIAL VARIAN	T/DISORDER SPE	ECIFIC PRENATAL T	ESTING						
Note: Prior to ordering testin requirements/). For complex 1-800-411-4363.									
1522 Custom Sequer	nce Analysis - Prer	natal			6109	MECP2	Deletion/Dupli	cation Analysis	
6099 Huntington Dise	ease Repeat Expan	sion Analysis			6351	DMD De	eletion/Duplica	tion Analysis	
6100 IKBKG Common	Deletion Analysis				6574	FMR1 (F	Fragile X) CGG	Repeat Expansion Ar	alysis
6105 Myotonic Dystro	ophy Type 1 Repeat	t Expansion Analysis							
					1	,			
Name of Baylor Genetic Cour	ıselor				Date (MM/D	/ D/YYYY)		-	
Gene Name					Baylor Gen	etics Fami	ily #		
ariant Information: c.					p				
(REQUIRED) Attached Fam	ilial Variant Repor	t							
PRENATAL TESTING OPTION IMPORTANT INSTRUCTIONS for control and MCC studies	DNS 5 FOR CMA and/or . Label with name,	FETAL MOLECULAR DOB, and complete	R STUDIES: the Parenta	Parental and Il and Familia	l Samples se • REFLE	ction abov	ve. IES		·····
IMPORTANT INSTRUCTIONS for control and MCC studies CONCURRENT STUDIES	DNS 5 FOR CMA and/or . Label with name,	FETAL MOLECULAR DOB, and complete	R STUDIES: the Parenta	Parental and Il and Familia	I Samples se • REFLE (Please	ction abov EX STUD e see conc	ve. IES ······ current testing		l orders)
PRENATAL TESTING OPTIC IMPORTANT INSTRUCTIONS for control and MCC studies CONCURRENT STUDIES	DNS 5 FOR CMA and/or . Label with name, studies should be o	FETAL MOLECULAR DOB, and complete t done reflexively)	R STUDIES: the Parenta	Parental and I and Familia	I Samples se • REFLE (Please	ction abov EX STUD e see conc romosom	ve. IES ······ current testing	column for additiona	ıl orders) ırmal, add: **
PRENATAL TESTING OPTIC IMPORTANT INSTRUCTIONS for control and MCC studies CONCURRENT STUDIES (Please see reflex column if	DNS 5 FOR CMA and/or . Label with name, 	FETAL MOLECULAR DOB, and complete t done reflexively)	R STUDIES: the Parenta	Parental and I and Familia	l Samples se • REFLE (Please Ch	EX STUD EX STUD e see conc romosom Expa	ve. IES current testing ne Analysis - If (anded CMA	column for additiona chromosomes are no O Targeted CN	ıl orders) ırmal, add: **
PRENATAL TESTING OPTIO IMPORTANT INSTRUCTIONS for control and MCC studies CONCURRENT STUDIES (Please see reflex column if AFAFP + AChE* AFAFP* Aneuploidy FISH (For 13, 18, 21	DNS 5 FOR CMA and/or . Label with name, 	FETAL MOLECULAR DOB, and complete t done reflexively)	R STUDIES: the Parenta	Parental and I and Familia	I Samples se REFLE (Please Ch An	ction abov EX STUD e see cond romosom Expa euploidy I Expa euploidy F	ve. IES current testing he Analysis - If of anded CMA FISH and Chron anded CMA	column for additiona chromosomes are no O Targeted CM nosome Analysis - If O Targeted CM osome Analysis - If chr	il orders) Irmal, add: ** 1A FISH is normal, add: ** 1A romosomes are normal, add:
PRENATAL TESTING OPTIO IMPORTANT INSTRUCTIONS for control and MCC studies CONCURRENT STUDIES (Please see reflex column if AFAFP + AChE* AFAFP* Aneuploidy FISH (For 13, 18, 21 X and Y; chromosomes or CMA must also be ordered)	DNS 5 FOR CMA and/or Label with name, studies should be of AF 8550 8550	FETAL MOLECULAR DOB, and complete to done reflexively) CVS	R STUDIES: the Parenta	Parental and I and Familia	I Samples se REFLE (Please Ch An An An	EX STUD EX STUD e see conc romosom O Expa euploidy I O Expa euploidy F O Expa	ve. IES current testing ne Analysis - If of anded CMA FISH and Chrom anded CMA FISH and Chromo anded CMA	column for additiona chromosomes are no O Targeted CN mosome Analysis - If O Targeted CN osome Analysis - If chr O Targeted CN	il orders) Irmal, add: ** 1A FISH is normal, add: ** 1A romosomes are normal, add:
PRENATAL TESTING OPTIO IMPORTANT INSTRUCTIONS for control and MCC studies CONCURRENT STUDIES (Please see reflex column if st AFAFP + AChE* AFAFP* Aneuploidy FISH (For 13, 18, 21 X and Y; chromosomes or CMA	DNS 5 FOR CMA and/or Label with name, studies should be of AF 8550 8550	FETAL MOLECULAR DOB, and complete to done reflexively) CVS	R STUDIES: the Parenta Blood	Parental and I and Familia	I Samples se REFLE (Please Ch An An An An An An An An An	Ction about CX STUD See concern Comosom C Expanded Expanded C Expanded C Expanded	ve. IES current testing ne Analysis - If (anded CMA FISH and Chron anded CMA FISH and Chroma anded CMA or Potential Ada	column for additiona chromosomes are no O Targeted CN mosome Analysis - If O Targeted CN osome Analysis - If chr O Targeted CN	il orders) Irmal, add: ** 1A FISH is normal, add: ** 1A romosomes are normal, add:
PRENATAL TESTING OPTIO IMPORTANT INSTRUCTIONS for control and MCC studies CONCURRENT STUDIES (Please see reflex column if AFAFP + AChE* AFAFP* Aneuploidy FISH (For 13, 18, 21 X and Y; chromosomes or CMA must also be ordered) Rapid FISH (13, 18, 21, X, Y) Chromosome Analysis	DNS 5 FOR CMA and/or Label with name, studies should be of AF 8550 8501 1, 8410	CVS	R STUDIES: the Parenta Blood 8425 8600	Parental and I and Familia Tissue/POC	I Samples se REFLE (Please Ch An An An An An An An An An	Ction about CX STUD See concern Comosom C Expanded Expanded C Expanded C Expanded	ve. IES current testing ne Analysis - If (anded CMA FISH and Chron anded CMA FISH and Chroma anded CMA or Potential Ada	column for additiona chromosomes are no O Targeted CN mosome Analysis - If O Targeted CN osome Analysis - If chu O Targeted CN d-On Testing	il orders) Irmal, add: ** 1A FISH is normal, add: ** 1A romosomes are normal, add:
PRENATAL TESTING OPTIO IMPORTANT INSTRUCTIONS for control and MCC studies CONCURRENT STUDIES (Please see reflex column if standard AFAFP + AChE* AFAFP* Aneuploidy FISH (For 13, 18, 21 X and Y; chromosomes or CMA must also be ordered) Rapid FISH (13, 18, 21, X, Y) Chromosome Analysis CMA Comprehensive	DNS 5 FOR CMA and/or . Label with name, . studies should be of AF 8550 8501 . 8410 . 8430	CVS	Blood	Parental and I and Familia Tissue/POC	I Samples se REFLE (Please Ch An An An An Plea Plea An	ction about EX STUD e see conc romosom C Expa euploidy I C Expa euploidy F C Expa ld Cells for ease spec	ve. IES current testing ne Analysis - If (anded CMA FISH and Chrom anded CMA FISH and Chrom anded CMA or Potential Add ify potential ad	column for additiona chromosomes are no O Targeted CM nosome Analysis - If O Targeted CM osome Analysis - If chr O Targeted CM d-On Testing d-on test(s) below:	il orders) Irmal, add: ** 1A FISH is normal, add: ** 1A romosomes are normal, add: 1A
PRENATAL TESTING OPTIO IMPORTANT INSTRUCTIONS for control and MCC studies CONCURRENT STUDIES (Please see reflex column if signature) AFAFP + AChE* AFAFP* Aneuploidy FISH (For 13, 18, 21 X and Y; chromosomes or CMA must also be ordered) Rapid FISH (13, 18, 21, X, Y) Chromosome Analysis CMA Comprehensive Expanded CMA	DNS 5 FOR CMA and/or Label with name, studies should be of AF 8550 8501 1, 8410	CVS	R STUDIES: the Parenta Blood 8425 8600	Parental and I and Familia Tissue/POC	I Samples se REFLE (Please Ch An An An An Ple FETAL	Ction above CX STUD See concern C Expanding C Expandi	ve. IES current testing ne Analysis - If (anded CMA FISH and Chrom anded CMA FISH and Chrom anded CMA or Potential Add ify potential ad	column for additiona chromosomes are no O Targeted CN mosome Analysis - If O Targeted CN osome Analysis - If chu O Targeted CN d-On Testing	il orders) Irmal, add: ** 1A FISH is normal, add: ** 1A romosomes are normal, add: 1A
PRENATAL TESTING OPTIO IMPORTANT INSTRUCTIONS for control and MCC studies CONCURRENT STUDIES (Please see reflex column if standard AFAFP + AChE* AFAFP* Aneuploidy FISH (For 13, 18, 21 X and Y; chromosomes or CMA must also be ordered) Rapid FISH (13, 18, 21, X, Y) Chromosome Analysis CMA Comprehensive	DNS 5 FOR CMA and/or . Label with name, . studies should be of AF 8550 8501 . 8410 . 8430	CVS	R STUDIES: the Parenta Blood 8425 8600	Parental and I and Familia Tissue/POC	I Samples se REFLE (Please Ch An An An Ple FETAL S89	ction abov EX STUD e see conc romosom C Expa euploidy I C Expa euploidy F C Expa ld Cells for ease spec VIRAL S 40 Her	ve. IES current testing he Analysis - If (anded CMA FISH and Chron anded CMA CISH and Chroma anded CMA for Potential Add ify potential add STUDIES SEN rpes Simplex V	column for additiona chromosomes are no O Targeted CM nosome Analysis - If O Targeted CM osome Analysis - If chr O Targeted CM d-On Testing d-on test(s) below: IDOUT (AMNIOTIC irus, 1 & 2	il orders) Irmal, add: ** 1A FISH is normal, add: ** 1A romosomes are normal, add: 1A
PRENATAL TESTING OPTIO IMPORTANT INSTRUCTIONS for control and MCC studies CONCURRENT STUDIES (Please see reflex column if standard AFAFP + AChE* AFAFP* Aneuploidy FISH (For 13, 18, 21 X and Y; chromosomes or CMA must also be ordered) Rapid FISH (13, 18, 21, X, Y) Chromosome Analysis CMA Comprehensive Expanded CMA Expanded CMA + Limited	DNS 5 FOR CMA and/or . Label with name, studies should be of AF 8550 8501 1, 8410 8410 8670	FETAL MOLECULAR DOB, and complete t done reflexively) CVS B410 B8410 B700 B700	R STUDIES: the Parenta Blood 8425 8600	Parental and I and Familia Tissue/POC	I Samples se REFLE (Please Ch An An An Ple FETAL 89 - 89	ction abov EX STUD e see conc romosom Expa euploidy I Expa euploidy F Expa euploidy F Expa	ve. IES current testing te Analysis - If (anded CMA FISH and Chromanded CMA FISH and Chromanded CMA for Potential Add or Potential Add ify potential add STUDIES SEN rpes Simplex V comegalovirus (column for additiona chromosomes are no O Targeted CM nosome Analysis - If O Targeted CM osome Analysis - If chr O Targeted CM d-On Testing Id-on test(s) below:	il orders) Irmal, add: ** 1A FISH is normal, add: ** 1A romosomes are normal, add: 1A
PRENATAL TESTING OPTIO IMPORTANT INSTRUCTIONS for control and MCC studies CONCURRENT STUDIES (Please see reflex column if signature) AFAFP + AChE* AFAFP* Aneuploidy FISH (For 13, 18, 21 X and Y; chromosomes or CMA must also be ordered) Rapid FISH (13, 18, 21, X, Y) Chromosome Analysis CMA Comprehensive Expanded CMA Expanded CMA + Limited Chromosome Analysis	DNS 5 FOR CMA and/or . Label with name, studies should be of AF 8550 8550 8501 8410 8670 8675	FETAL MOLECULAR DOB, and complete to done reflexively) CVS B8410 8700 8671 8676	R STUDIES: the Parenta Blood 8425 8600	Parental and I and Familia Tissue/POC	I Samples se REFLE (Please Ch An An An Ple FETAL S89	ction abov EX STUD e see conc romosom C Expa euploidy I C Expa euploidy F C Expa ld Cells for ease spec VIRAL S 40 Her 45 Cyt 50 Tox	ve. IES current testing he Analysis - If (anded CMA FISH and Chron anded CMA CISH and Chroma anded CMA for Potential Add ify potential add STUDIES SEN rpes Simplex V	column for additiona chromosomes are no O Targeted CM nosome Analysis - If O Targeted CM osome Analysis - If chr O Targeted CM d-On Testing d-On Testing d-On Test(s) below: IDOUT (AMNIOTIC irus, 1 & 2 (CMV) D) gondii	il orders) Irmal, add: ** 1A FISH is normal, add: ** 1A romosomes are normal, add: 1A

Note: Extracted DNA samples are not accepted for CMA + Limited Chromosome Analysis.

Additional testing information and requisitions are available at www.baylorgenetics.com.



INFORMED CONSENT FOR PRENATAL TESTING

Fotus of				/ /		
Fetus of:	Patient Last Name	Patient First Name	MI	Date of Birth (MM / DD / YYYY)	Genetic Sex	
TEST INFO	ORMATION					
		egarding prenatal genetic testing, which you sl I limitations of this testing, we have provided in		, , ,		
Th	an of proposal gonatic testing is to prodict if	fo potiont's programa where a genetic disease a	ia at an inaraa	and rick to dovelop a genetic disease.	DNA is the genetic	

The purpose of prenatal genetic testing is to predict if a patient's pregnancy has a genetic disease or is at an increased risk to develop a genetic disease. DNA is the genetic material that we receive from our parents. Genes are made of DNA and are the instructions for maintaining the health of our body. Each person has a unique set of DNA and most of the differences in our DNA do not impact our health. Genetic testing analyzes DNA to find changes (also called mutations or variants) in a pregnancy that might cause disease or make it more likely to develop disease. Prenatal testing is typically performed if there is a known family history of a genetic disease and/or other clinical findings are identified about a pregnancy that are suggestive of a genetic disease. Once the results of testing become available, you should discuss the significance of these results with your healthcare provider or genetic counselor.

For the purposes of this consent, prenatal genetic testing might be performed on a single fetus or multiple fetuses of the same pregnancy (e.g., twin gestation)

Depending on the reason genetic testing is offered, your pregnancy might be tested for:

- A known variant that has already been found in your family.
- A single gene or variant that causes a specific, suspected disease.
- Multiple genes at the same time. These genes might cause similar diseases or might cause diseases that are unrelated to each other.

Multiple types of testing may be performed. Each test may be used to identify different variants or diseases.

RESULTS

There are several types of test results that may be reported including:

- **Positive:** Positive, "abnormal", or "detected" results mean there is a change in the DNA of the pregnancy that is predicted to cause a genetic disease and/or that the pregnancy is at an increased risk of developing a disease in the future. It is possible for a pregnancy to test positive for more than one variant. Positive results might include pathogenic variants (variants known to be associated with disease) and likely pathogenic variants (variants that are likely to be associated with disease).
- **Negative:** Negative, "normal", or "not detected" results mean the DNA of the pregnancy was not identified to have changes associated with a genetic disease. This might indicate that there are no variants associated with disease in the DNA tested. Genetic testing, while highly accurate, might not detect a variant present in the DNA tested. This can be due to limitations of the information available about the gene(s) being tested, or limitations of the testing technology.
- Variant of Uncertain Clinical Significance: Testing can detect variant(s) in DNA which we do not yet fully understand. These are also referred to as variants of uncertain clinical significance (VUS). Additional testing may be recommended for your pregnancy if a VUS is identified.
- Secondary / Incidental Findings: Testing can sometimes detect a variant in the DNA unrelated to the reason for testing. If this variant is expected to have medical or reproductive significance, it is called a secondary or incidental finding.

CONSIDERATIONS AND LIMITATIONS

- This consent form can be used for most types of prenatal testing. If prenatal Huntington disease (HD) testing or whole exome sequencing (WES) is needed, there is a separate consent form for these tests. Consent forms for other tests are located at Baylor Genetics' website (https://www.baylorgenetics.com/consent/).
- Results may indicate your pregnancy has a genetic disease or is at increased risk to develop a genetic disease.
- It is important to understand that genetic tests, even if negative, cannot rule out every variant or every condition. It is not possible to exclude risks for all genetic diseases for your pregnancy.
- It is possible that even if the test identifies the underlying genetic cause for clinical findings in your pregnancy this information may not help in predicting the severity or progression of disease or change management or treatment of disease.
- Depending on the type of genetic testing performed and the results, additional genetic testing or other testing may be needed to fully understand the likelihood of your pregnancy developing the disease or the severity of the disease. This additional testing might need to be performed on your pregnancy or other members of your family and will be discussed by your health care provider.
- It is recommended that you discuss genetic testing with your healthcare provider or genetic counselor before signing this consent and again after results are made available.
- It may not always be possible to complete testing, as sometimes the sample does not have enough DNA to perform testing or for other reasons. In these cases, another sample may need to be sent to the laboratory to perform the testing.
- Parental samples are highly recommended when prenatal genetic testing is performed. They are used as control samples to ensure accurate prenatal results are issued.



G

INFORMED CONSENT FOR PRENATAL TESTING

Fetus of:	Der de la del	
	Patient Last Name	

Patient First Name

MI

1 Date of Birth (MM / DD / YYYY)

1

Genetic Sex

PATIENT CONFIDENTIALITY AND SPECIMEN RETENTION

- If several family members are tested, the correct interpretation of the results depends on the information provided about the relationships among family members. In rare cases, genetic testing can reveal that the true biological relationships in a family are not as they were reported. If a difference is identified, it may be necessary to share this information with the healthcare provider who ordered the testing.
- Genetic testing is highly accurate, however in rare cases, inaccurate results may occur. Reasons for this include, but are not limited to, mislabeled samples, inaccurate reporting of clinical/medical information, or rare technical errors.
- If you sign this consent form, but you no longer wish to have your sample(s) tested, you can contact the healthcare provider who ordered the test to cancel the test. If you wish to cancel testing, the laboratory must be notified of the cancellation request before 5 PM CST the business day after the sample has been received by Baylor Genetics. If the laboratory is not notified of your cancellation request until after this time, you will be charged for the full cost of the test.
- Only Baylor Genetics and Baylor Genetics contracted partners will have access to the sample(s) provided to conduct the requested testing. Results will only be released to the following person(s): (i) a licensed healthcare provider, (ii) those authorized in writing, (iii) the patient or their personal representative, and (iv) those allowed access to test results by law. I understand that I have the right to access my test results directly from Baylor Genetics by providing a written request. I also understand that laboratory raw data can be requested by providing a written request or HIPAA Authorization Form.
- In rare cases, persons with genetic diagnoses have experienced problems with insurance coverage and employment. The U.S. Federal Government has enacted several. laws that prohibit discrimination based on genetic test results by health insurance companies and employers. In addition, these laws prohibit unauthorized disclosure of this information. For more information, you can visit www.genome.gov/10002077.
- Samples will be retained in the laboratory in accordance with the laboratory retention policy.
- After testing is complete, the de-identified submitted specimen may be used for test development and improvement, internal validation, quality assurance, and training purposes. DNA specimens are not returned to individuals or to referring heath care providers unless specific prior arrangements have been made.
- By signing this consent form, I understand and agree that variants identified may also be submitted to public databases, such as ClinVar. Such submission serves to contribute knowledge to the medical community. I understand that limited clinical information is also required for the submission of information to ClinVar's database and further that the contents of this limited clinical information may, although unlikely, include information that may identify me personally.
- Samples from residents of New York State will not be included in general research studies without your written consent and will not be retained for more than 60 days after receipt of the sample, unless specifically authorized by your selection below. No tests other than those authorized shall be performed on the biological sample.

FOR SAMPLES SUBMITTED FROM NEW YORK STATE ······

Initial

I understand that no genetic test other than those I have authorized shall be performed on my biological sample, and the sample will be destroyed at the end of testing or not more than 60 days after the sample was taken. However, by initialing here, I hereby authorize the lab to retain my sample(s) for longer retention in accordance with the laboratory retention policy for internal laboratory quality assurance studies and possible research testing.

FINANCIAL AGREEMENT AND GUARANTEE

By signing this consent form. Laccent full and complete financial responsibility for all genetic testing ordered by my healthcare provider. For insurance billing, I bereby authorize Baylor Genetics to bill my health insurance plan on my behalf, and further authorize Baylor Genetics to release any information to my insurance carrier which is reasonably required for billing. I additionally designate Baylor Genetics as my designated representative for purposes of appealing any denial of benefits by my insurance carrier. I irrevocably assign associated payment to Baylor Genetics, and direct that payment be made directly to Baylor Genetics. I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by Baylor Genetics as part of a verification of benefits investigation. I agree to be financially responsible for all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to me for unpaid services performed by Baylor Genetics on my behalf, I agree to endorse the insurance check as appropriate and forward such check to Baylor Genetics within thirty (30) days of receipt thereof, as payment towards Baylor Genetics' claim for services rendered. If I do not have health insurance, I agree to pay for the full cost of the genetic testing that was ordered by my healthcare provider and billed to me by Baylor Genetics.

If my health insurer does not cover the test or I do not have health insurance, I have received a good faith estimate of the cost for the genetic testing ordered by my provider and agree to pay for the cost of the genetic testing billed to me by Baylor Genetics based on that good faith estimate. More information is available in Baylor Genetics' No Surprises Act and Good Faith Estimate Notice located at https://www.baylorgenetics.com/no-surprises-act/.

I understand that a completed Advance Beneficiary Notice (ABN) is required for Medicare fee for service patients if the service is not payable by Medicare as not medically necessary or reasonable.

RECONTACT FOR RESEARCH CONSENT

Baylor Genetics participates in research relating to health, disease prevention, drug development, and other scientific purposes. Baylor Genetics may contact patients or their provider(s) directly as part of this research. I agree to allow Baylor Genetics to contact me or my provider(s) about possible research involving the sample(s) and/or information associated with this testing. I understand that patients generally receive no compensation for this participation in research. For more information on research at Baylor Genetics, please visit baylorgenetics.com.

If I wish to opt out of being recontacted for research purposes by Baylor Genetics, I understand that I may check the box below:

Please do not contact me regarding any research that uses information obtained from this testing.

For any research I may be contacted about, I prefer contact through the following methods (please check all that apply – if no choices are selected, contact via secure email will be made if an email address is provided):

Email Phone Mail

5 // 6

PHONE 1.800.411.4363 FAX 1.800.434.9850



INFORMED CONSENT FOR PRENATAL TESTING

				/ /			
Fetus of:	Patient Last Name	Patient First Name	MI	Date of Birth (MM / DD	/ YYYY)	Genetic Sex	
PATIENT	AUTHORIZATION						
explanation mportance	ons from my healthcare provide ce of genetic counseling and hav	nowledge that I have read, understand, and here r about the planned genetic test(s) and possible r e been provided with written information identify wered and I have had the necessary time to make	esults. I have been info ving a genetic counselo	rmed by my healthcare p r or medical geneticist wh	rovider about t	he availability	and
hereby g	ive permission to Baylor Genetic	cs to conduct prenatal genetic testing as ordered	by my physician.				
					/	/	
Patient (M	aternal) Name	Patient's (Maternal)	Signature		Date Signe	ed (MM / DD / Y	YYY)
					/	1	
Patient's F	Personal Representative* Name	Patient's Personal F	Representative Signatur	e	Date Signe	ed (MM / DD / Y	YYY)
Relationsh	nip of Personal Representative* to	o the Patient					
					/	/	
Paternal N	lame	Paternal Signature			Date Signe	ed (MM / DD / Y	YYY)
					/	/	
Paternal P	Personal Representative* Name	Paternal Personal F	Representative Signatur	e	Date Signe	ed (MM / DD / Y	YYY)
Relationsh	nip of Paternal Personal Represe	ntative					
					/	1	
Ordering F	Provider's Signature				Date Signe	ed (MM / DD / Y	YYY)
	ROGATE PREGNANCIES						
6N 30N	ROOATE REONANCIES						

Maternal cell contamination (MCC) studies are performed using a sample of blood or buccal cells from a pregnant person. MCC studies are used to exclude the presence of any DNA from the pregnant person in the fetal DNA sample. The results of MCC studies are not used for the treatment or management of the fetus, pregnant person or gamete (egg/ sperm) donor, and the data generated are not part of the pregnant person's designated record.

I hereby give permission for my sample to be used for MCC studies:

Surrogate Printed Name

Surrogate Signature

Date Signed (MM / DD / YYYY)

* If you are signing on behalf of the patient as the parent(s) and/or person with legal authority to act on behalf of the patient, you may be required to provide evidence of your authority.